Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020 Sep; 7(9):e660-e670.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Agents, Immunological
Disease Progression
Drug Therapy, Combination
Female
Hodgkin Disease
Humans
Hypersensitivity
Ipilimumab
Male
Middle Aged
Pain
Recurrence
Survival Rate
Treatment Outcome